According to our new research study on “Skin Graft Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Graft Thickness, Applications, Equipment, and End Users,” the market is expected to reach US$ 1,673.5 million by 2028 from US$ 985.4 million in 2020. It is estimated to grow at a CAGR of 7.0% from 2021 to 2028.
Skin grafting is a surgery involving the transplantation of skin using various types of skin graft. Skin grafts are also used to treat extensive wounding or trauma and burns. Skin graft is small patch of skin, which is removed from skin of the other part of the patient’s body by a surgery. The patch of skin is transplanted or attached to the injured sit or the burnt site.
Skin grafts are ideally preferred post-surgery for skin cancers. Skin grafts are generally referred for local postoperative radiotherapy (PORT) to ensure closure of surgical bed created during radiotherapy. According to Cancer Research UK, ~15,400 new melanoma skin cancer cases are registered in the UK every year, accounting for 42 new cases every day. Incidence rates for melanoma skin cancer are projected to rise by 7% in the UK between 2014 and 2035, to 32 cases per 100,000 people by 2035. Likewise, according to the recent statistics published by the International Agency for Research on Cancer, in 2020, 19.3 million new cancer cases were registered, excluding 18.1 million for nonmelanoma skin cancer. Thus, an increase in the prevalence of skin cancer is likely to contribute to skin grafting in the coming future.
Download sample PDF Copy https://www.theinsightpartners.com/sample/TIPHE100001099/
The growth of the skin graft is mainly attributed to factors such as increasing numbers of burn injuries, and rising prevalence of skin cancer and diabetes. However, the high cost of skin grafting procedures and alternatives for skin grafts hinders the market growth.
The key factors such as the increasing numbers of burn injuries and rising prevalence of skin cancer and diabetes drive the growth of the skin graft market. However, the high cost of skin grafting procedures and alternatives for skin grafts hinder the market growth.
Market leaders operating in the market have undertaken various organic and inorganic growth strategies in B. Braun Melsungen AG; Integra Life Sciences Corporation; Smith & Nephew; AVITA Medical; MiMedx; Organogenesis Inc; Tissue Regenix Group; Zimmer Biomet; De Soutter Medical; and Nouvag AG.
Several in organic approaches, such as product launches, and expansion in the skin graft, have resulted in the growth of the market. Likewise, inorganic strategies such as mergers & acquisitions, and collaboration have help the company to strengthen its revenue, which allows the company to hold a strong position in the market.
The list of the growth strategies done by the players operating in the Skin Graft:
·In Sep-2020 MiMedx Group, Inc. launched EpiCord Expandable, the latest advancement in its portfolio of products. At the core of this technology is EpiCord, which has demonstrated clinical efficacy in the treatment of diabetic foot ulcers.
·In May-2019 the company received contract for the PuraPly Antimicrobial (PuraPly AM), Apligraf, Dermagraft, NuShield and other products advanced wound care. Vizient, is one of the largest health care performance improvement company with over 3,100 hospital and health system members.
·In Apr-2019 Smith and Nephew has acquired skin substitute manufacturer Osiris Therapeutics for US$ 660 million. This acquisition is expected to expand Smith and Nephew’s portfolio in advanced wound management.
·In Jan-2019 The RECELL Autologous Cell Harvesting Device (RECELL System) was launched in the United States by AVITA Medical for the treatment of acute thermal burns in patients aged 18 and up.